# Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

> **NCT01522469** · PHASE2 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

## Interventions

- **DRUG:** Crenolanib Besylate (CP-868,596-26)

## Key facts

- **NCT ID:** NCT01522469
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522469, "Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01522469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*